Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Recruiting

Back to Antibody-Mediated Rejection trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(55 sites)

United States

Research Site, Birmingham, Alabama

Research Site, Scottsdale, Arizona

Research Site, Los Angeles, California

Research Site, Orange, California

Research Site, Tampa, Florida

Research Site, Atlanta, Georgia

Research Site, Kansas City, Kansas

Research Site, Ann Arbor, Michigan

Research Site, Detroit, Michigan

Research Site, Livingston, New Jersey

Research Site, New York, New York

Research Site, Durham, North Carolina

Research Site, Cincinnati, Ohio

Research Site, Philadelphia, Pennsylvania

Research Site, Charleston, South Carolina

Research Site, Dallas, Texas

Research Site, Houston, Texas

Research Site, Richmond, Virginia

Research Site, Seattle, Washington

Research Site, Milwaukee, Wisconsin

Brazil

Research Site, Botucatu

Research Site, Campinas

Research Site, Porto Alegre

Research Site, São Paulo

Canada

Research Site, Calgary, Alberta

Research Site, Edmonton, Alberta

Research Site, Vancouver, British Columbia

Research Site, London, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

China

Research Site, Changsha

Research Site, Guangzhou

Research Site, Nanning

Research Site, Shanghai

Research Site, Wuhan

Research Site, Xi'an

South Korea

Research Site, Seoul

Spain

Research Site, Barcelona

Research Site, Zaragoza

Taiwan

Research Site, Kaohsiung City

Research Site, Taichung

Research Site, Taoyuan District

United Kingdom

Research Site, Birmingham

Research Site, London